Fabio Bonilla-Abadía, Nicolás Coronel Restrepo, Gabriel J Tobón, Andrés F Echeverri, Evelyn Muñoz-Buitrón, Andres Mauricio Castro, Mercedes Andrade Bejarano, Carlos A Cañas
{"title":"Rituximab for remission induction and maintenance in refractory systemic lupus erythematosus.","authors":"Fabio Bonilla-Abadía, Nicolás Coronel Restrepo, Gabriel J Tobón, Andrés F Echeverri, Evelyn Muñoz-Buitrón, Andres Mauricio Castro, Mercedes Andrade Bejarano, Carlos A Cañas","doi":"10.1155/2014/731806","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment. </p>","PeriodicalId":46314,"journal":{"name":"Autoimmune Diseases","volume":"2014 ","pages":"731806"},"PeriodicalIF":1.7000,"publicationDate":"2014-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2014/731806","citationCount":"14","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Autoimmune Diseases","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2014/731806","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2014/1/16 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 14
Abstract
Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease with high morbidity if untreated. Sometimes, despite aggressive treatments, the disease remains active with cumulative organic damage. We conducted a retrospective and descriptive observational study of patients with SLE refractory to conventional treatment who were treated with rituximab (RTX) as remission induction therapy and maintenance. There was a significant reduction in the conventional immunosuppressive drug dose and the number of relapses of disease. RTX appeared to be effective and safe for the induction and maintenance of remission in patient with SLE refractory to conventional treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
